Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
Pediatrics, Sarcoma
Phase III
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics, Radiotherapy
Cyclophosphamide (CTX), Dactinomycin (actinomycin-D), Irinotecan, Radiation, Temsirolimus, Vincristine
Borinstein, Scott
Vanderbilt University


0 Years
Inclusion Criteria:

Feasibility Phase: Patients must be
Efficacy Phase: Patients must be =
Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon stage, group, and age, as below

RMS types included under embryonal rhabdomyosarcoma (ERMS) include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2013 World Health Organization (WHO) classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant); classification of alveolar rhabdomyosarcoma (ARMS) in the 2013 WHO classification is the same as in the ICR and includes classic and solid variants * ERMS ** Stage 1, group III (non-orbit) ** Stage 3, group I/II ** Stage 2/3, group III ** Stage 4, group IV,
Specimen Submission: Patients must have sufficient tissue available for the required biology study

Lansky performance status score >= 50 for patients == 50 for patients > 16 years of age

Peripheral absolute neutrophil count (ANC) >= 750/uL

Platelet count >= 75,000/uL

Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows: * 1 month to = 16 years old: 1.7 mg/dl (male), 1.4 mg/dl (female) * Patients with an elevated serum creatinine due to obstructive hydronephrosis secondary to tumor are still eligible; however, patients with urinary tract obstruction by tumor must have unimpeded urinary flow established via diversion (i.e. percutaneous nephrostomies or ureteric stents) of the urinary tract

Total bilirubin =
All patients and/or their parents or legal guardians must sign a written informed consent.

All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Exclusion Criteria:

Patients who have previously received temsirolimus, another mTOR inhibitor, or any other investigational agent

Patients who have received any chemotherapy (excluding steroids) and/or RT prior to this enrollment

Patients with uncontrolled hyperglycemia

Patients with uncontrolled hyperlipidemia

Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for at least 3 months after treatment is completed

Female patients who are pregnant are not eligible since fetal toxicities or teratogenic effects have been noted for several of the study drugs; Note: A pregnancy test is required for female patients of childbearing potential prior to study entry

Lactating females who plan to breastfeed their infants are not eligible

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: